Publications (2)6.76 Total impact
-
Article: Therapeutic effects and prognostic factors in high-intensity focused ultrasound combined with chemoembolisation for larger hepatocellular carcinoma.
[show abstract] [hide abstract]
ABSTRACT: The purpose of this study is to evaluate high-intensity focused ultrasound (HIFU) ablation combined with transcatheter arterial chemoembolisation (TACE) in the treatment of larger hepatocellular carcinoma (HCC). Eighty-nine (89) patients with unrespectable larger HCC were randomised into a TACE group (n=45) and a TACE plus HIFU group (n=44). Therapeutic effects were assessed at follow-up with physical examination, level of serum alpha-fetoprotein and computed tomography or magnetic resonance imaging. All patients were followed up to observe long-term therapeutic effects and evaluated prognostic factors for survival. No severe complication was observed. Follow-up images showed that total effective rate in tumour response accounted for 72.8% in the TACE-HIFU group, which were significantly higher than that of TACE group (44.5%, P<0.05). The 1-, 2-, 3- and 5-year overall survival rates for the TACE-HIFU group were 72.7%, 50.0%, 31.8% and 11.4%, respectively; correspondingly, for the TACE group were 47.2%, 16.7%, 2.8% and 0%, respectively (P<0.01). The 1-, 2-, 3- and 5-year disease-free survival rates for the TACE-HIFU group were 34.1%, 18.2%, 9.1% and 0%, respectively; correspondingly, for the TACE group were 13.9%, 5.6%, 0% and 0%, respectively (P<0.01). TNM stage, portal vein tumour thrombosis and Child-Pugh classification each had a significant effect on the survival. HIFU ablation combined with TACE is safe, effective and a promising approach for the treatment of larger HCC.European journal of cancer (Oxford, England: 1990) 09/2010; 46(13):2513-21. · 4.12 Impact Factor -
Article: Superficial malignant tumors: noninvasive treatment with ultrasonographically guided high-intensity focused ultrasound.
[show abstract] [hide abstract]
ABSTRACT: The purpose of this study was to evaluate the effectiveness of ultrasonographically guided high-intensity focused ultrasound (HIFU) ablation for superficial malignant tumors. HIFU ablation was applied to 38 cases. The diameter of tumors ranged from 1.5-18 cm, including < or =3 cm in seven cases, >3 to < or =5 cm in four cases, >5 to <10 cm in 15 cases, and > or =10 cm in 12 cases. Using imaging techniques, the volume and activity of tumors were observed before and after HIFU ablation, and the effectiveness of HIFU ablation in superficial malignant tumors was evaluated. For tumors < or =5 cm in diameter, HIFU ablation was completely effective in 100% (11/11) of cases; for tumors >5 cm in diameter, HIFU ablation was completely effective in 25.9% (7/27) of cases, partially effective in 14.8% (4/27) of cases, moderately effective in 33.3% (9/27) of cases; the disease remained stable in 14.8% (4/27) of cases and progressed in 11.1% (3/27) of cases. No significant difference was observed in the tumor volumes before (202.6 +/- 230.4 cm(3)) and 6-8 w after HIFU ablation (188.1 +/- 215.8 cm(3)). However, the difference in the active volume before (202.6 +/- 230.4 cm(3)) and after (127.6 +/- 189.7 cm(3)) HIFU ablation was statistically significant. Among 38 the cases, 32 reported painful symptoms, with a pain score of 4.39 +/- 2.36, before the ablation; the values dropped to 0.19 +/- 0.54 after HIFU, and the difference was statistically different. Thus, HIFU is a safe, effective and promising approach for the treatment of superficial malignant tumors.Cancer biology & therapy 12/2009; 8(24):2398-405. · 2.64 Impact Factor
